Industry
With our expertise and facilities, commercial ideas can go even further
GovGrant University Spinout Report 2021
Together, we can make a difference.
We have the knowledge, expertise, skills and facilities to springboard ideas with market potential and bring business ambitions to fruition.
We drive change by being bold, thinking outside the box, and investing in research and ideas with impact that make a difference.
From recent graduates to award-winning research experts, if you’re looking for academic support to enhance your business potential we can help.
There's no 'one-size-fits-all' route to success. Whether you’re a first-time collaborator or a longer-term partner, we offer a variety of services to meet your needs – from projects, consultancy and facility services, to licensable technologies and commercialisation.
Through fundamental science breakthroughs, spinning out innovative businesses, and finding ways of improving the world around us, the work we do with our industry partners is transforming lives, and helping us make a difference both locally and globally.
Talk to us today to explore how we can help you achieve your goals.
Guardian University Guide 2021
Reuters 2017
We are a world-class institution, with world-leading technology experts, research and advanced research facilities. Our innovation culture involves working with large and small partners to turn technology ideas into commercial realities. Together we can go even further.
Industry stories from the University of Dundee

Press release
Floating wind farms of the future could be installed further into deep water after University of Dundee experts unveiled plans to develop revolutionary new anchoring technology and analysis techniques.

Press release
The University of Dundee and the Association of British HealthTech Industries (ABHI) will work together to develop innovative healthcare technologies for the benefit of patients and health services across the world.

Press release
University of Dundee spinout Amphista Therapeutics will work with global biopharmaceutical companies as part of strategic collaborations potentially worth more than $2 billion.
Professor Amin Abdolvand
